• About us
  • Contact us
  • Our team
  • Terms of Service
Thursday, July 17, 2025
Kashmir Images - Latest News Update
Epaper
  • TOP NEWS
  • CITY & TOWNS
  • LOCAL
  • BUSINESS
  • NATION
  • WORLD
  • SPORTS
  • OPINION
    • EDITORIAL
    • ON HERITAGE
    • CREATIVE BEATS
    • INTERALIA
    • WIDE ANGLE
    • OTHER VIEW
    • ART SPACE
  • Photo Gallery
  • CARTOON
  • EPAPER
No Result
View All Result
Kashmir Images - Latest News Update
No Result
View All Result
Home TOP NEWS

Covaxin out of clinical trial mode, granted restricted emergency use authorisation

Press Trust of india by Press Trust of india
March 12, 2021
in TOP NEWS
A A
0
Centre issues Letter of Comfort to Bharat Biotech for 45 lakh doses of Covaxin
FacebookTwitterWhatsapp

New Delhi: The Centre on Thursday said Bharat Biotech’s indigenously developed Covaxin is out of the “clinical trial mode” and that it has now been granted the regular restricted emergency use authorisation just like Covishield manufactured by Serum Institute.

Addressing a weekly press conference, NITI Aayog member (Health) Dr V K Paul said Covaxin and Covishield have the same licensure status now.

Related posts

Valley all set to welcome Amarnath Yatris

On completing 5 years in office, LG says, Naya Kashmir is here

July 17, 2025
Fight against drug menace, terrorism on the same pedestal: DGP

Terrorist killed recently in Basantgarh was top JeM commander Haider: DGP

July 17, 2025

“The condition of it (Covaxin) being required to be administered under clinical trial mode is no more there,” Paul said.

“Both the COVID-19 vaccines Covaxin and Covishield have the same licensure status. It has already being given to around 19 lakh people. Covaxin has stood the test of time in terms of great safety. Only 311 individuals had minimal side effects. It is the triumph for India’s research and development enterprise and science and technology enterprise,” he said.

India’s drug regulator on January 03 had granted permission for the restricted use of Covaxin in emergency situations in the public interest as an abundant precaution, in clinical trial mode, especially in case of infection by mutant strains.

The Subject Expert Panel on COVID-19 of the CDSCO had recommended granting emergency use authorisation to Bharat Biotech’s indigenously developed Covaxin while removing the condition for the vaccine to be administered in “clinical trial mode”.

The Drugs Controller General of India (DCGI) in a communique to Bharat Biotech said, “Accordingly, based on the recommendations of the SEC, the condition, ‘this permission is for restricted use in emergency situation in public interest as an abundant precaution in clinical trial mode’ in the permission is amended to read as this permission is for restricted use in emergency situation in public interest.”

“However, you are required to continue ongoing phase-3 clinical trial as per approved clinical trial protocol and submit revised summary of product characteristics, prescribing information and fact sheet,” it said.

Replying to a question whether the government has a timeline in mind for phase 3 vaccination drive and who gets included in that, Paul said, “We are now focused on the relatively large group of individuals above the age of 60 as well as those aged 45-60 with comorbidities. We are building a momentum to cover this significantly large group.”

“We will see progress and moving forward, yes, further increase in the circle of those who are eligible will be considered,” Paul said.

 

Previous Post

COVID-19: Centre says don’t lower guard, pandemic not yet over

Next Post

Hizb militant, 3 ‘associates’ chargesheeted: Police

Press Trust of india

Press Trust of india

Next Post
Journalist among 10 charge-sheeted in terror case

Hizb militant, 3 ‘associates’ chargesheeted: Police

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

ePaper

  • About us
  • Contact us
  • Our team
  • Terms of Service
E-Mailus: kashmirimages123@gmail.com

© 2024 Kashmir Images - Designed by GITS.

No Result
View All Result
  • TOP NEWS
  • CITY & TOWNS
  • LOCAL
  • BUSINESS
  • NATION
  • WORLD
  • SPORTS
  • OPINION
    • EDITORIAL
    • ON HERITAGE
    • CREATIVE BEATS
    • INTERALIA
    • WIDE ANGLE
    • OTHER VIEW
    • ART SPACE
  • Photo Gallery
  • CARTOON
  • EPAPER

© 2024 Kashmir Images - Designed by GITS.